BREAKING: Futures Fall On Weak Microsoft Guidance
Cassava Sciences (SAVA) disappointed investors Tuesday with midstage results for its oral Alzheimer’s treatment and SAVA stock plummeted by a double-digit percentage.
The company enrolled more than 200 patients with mild to moderate Alzheimer’s disease in a midstage study of its experimental pill, simufilam. Patients took two doses a day for a year and, on average, their symptoms were “minimally changed.”
Cassava says when symptoms change minimally or improve over a year that “is a highly desirable outcome” in this patient population.
But the results paled in comparison to earlier reports from Cassava, and SAVA stock plunged 19.2% and closed at 29.44 on the stock market today.
The results are from Cassava’s open-label study, meaning patients knew they were taking the test drug.
Cassava says 47% of patients who reached the one-year mark showed improvements in their symptoms, as measured by the Alzheimer’s Disease Assessment Scale-Cognitive Subscale. Of those patients, they showed an average 4.7-point improvement on a 70-point scale.
Another 23% of patients declined less than 5 points over the year. These patients declined by 2.5 points on average.
But in September 2021, the company unveiled the results for the first 50 patients. Of those, 68% showed an improvement on the same scale. On average, they had a 6.8-point improvement. Last August, Cassava had results for the first 100 patients. In that group, 63% improved by an average 5.6 points.
In the first 50 patients, scores improved by 3.2 points. Among the first 100 patients, that dropped to a 1.5-point improvement. In the new release, Cassava noted the total scores declined by 0.5 points across all patients. That likely hammered SAVA stock.
It’s important to note, the results were mixed between mild and moderate patients. Scores of symptoms improved by 2.4 points in mild patients. In moderate patients, the scores worsened by 4.4 points.
The Alzheimer’s treatment was safe and well tolerated, Cassava said. There were no drug-related serious side effects.
“I am very excited about these one-year data,” Cassava Chief Executive Remi Barbier said in a written statement. “They add strength and determination to our goal of helping people fight Alzheimer’s disease.”
Before Tuesday’s release, SAVA stock was forming a double-bottom base with a buy point at 45.53, according to MarketSmith.com. Shares tumbled below that chart pattern after Cassava posted the results.
Still, Cassava stock has a strong Relative Strength Rating of 93 out of a best-possible 99, IBD Digital shows. This puts SAVA stock in the leading 7% of all stocks in terms of 12-month performance.
Follow Allison Gatlin on Twitter at @IBD_AGatlin.
YOU MAY ALSO LIKE:
How J&J’s Mostly Defunct Covid Shot Still Managed To Hamper Sales; Danaher Dives
No. 1 IBD 50 Stock Catalyst Tanks As Teva Looks To Knock Off Its Only Product
Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists
Get Stock Ideas From IBD Experts Each Morning Before The Open
Find The Best Long-Term Investments With IBD Long-Term Leaders
1/18/2023 Cassava Sciences shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 70 to 87.
1/18/2023 Cassava Sciences shows rising price performance, earning an upgrade to…
Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20!
Get market updates, educational videos, webinars, and stock analysis.
Learn how you can make more money with IBD’s investing tools, top-performing stock lists, and educational content.
Notice: Information contained herein is not and should not be construed as an offer, solicitation, or recommendation to buy or sell securities. The information has been obtained from sources we believe to be reliable; however no guarantee is made or implied with respect to its accuracy, timeliness, or completeness. Authors may own the stocks they discuss. The information and content are subject to change without notice.
*Real-time prices by Nasdaq Last Sale. Realtime quote and/or trade prices are not sourced from all markets.
Ownership data provided by Refinitiv and Estimates data provided by FactSet.
© 2000-2023 Investor’s Business Daily, LLC. All rights reserved
